<DOC>
	<DOCNO>NCT01641666</DOCNO>
	<brief_summary>This study design assess safety tolerability boceprevir dose 800 mg three time daily ( TID ) orally ( PO ) combination Peginterferon alfa-2b ( PEG2b ) 1.5 mcg/kg week ( QW ) administer subcutaneously ( SC ) plus ribavirin ( RBV ) ( 800 1400 mg/day ) PO Response Guided Therapy ( RGT ) adult Vietnamese subject Chronic Hepatitis C , Genotype 1 ( CHC GT1 ) fail prior treatment interferon ribavirin Vietnam .</brief_summary>
	<brief_title>Safety Tolerability Boceprevir Combination With Peginterferon Alfa-2b Plus Ribavirin Treatment Vietnamese Subjects With Chronic Hepatitis C Genotype 1 ( P08599 )</brief_title>
	<detailed_description>Each participant participate trial maximum 80 week time participant sign Informed Consent Form ( ICF ) final contact . After Screening phase approximately 4 8 week , participant receive treatment approximately 36-48 week depend response Treatment Week 8 . A 4-week lead-in period PEG2b plus RBV follow 32 week boceprevir plus PEG2b/RBV . At treatment Week 36 participant assign follow treatment depend virologic response Week 8 cirrhotic status : 1 . For non-cirrhotic participant undetectable hepatitis C virus ( HCV ) -RNA Week 8 , treatment discontinue Week 36 . 2 . For non-cirrhotic participant detectable HCV-RNA Week 8 , boceprevir treatment discontinue Week 36 PEG2b RBV treatment continue Week 48 . 3 . For cirrhotic participant , boceprevir plus PEG2b/RBV treatment continue Week 48 . The study futility rule Week 12 point subject detectable HCV-RNA level discontinue . All participant post-treatment follow-up period least 24 week .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Weight ≥ 40 kg ≤ 125 kg Sexually active male participant female participant childbearing potential must agree use medically acceptable form contraception Must document Chronic Hepatitis C Genotype 1 infection Must fail prior treatment interferon plus ribavirin Must complete treatment interferon plus ribavirin least 12 week Must liver biopsy Fibroscan determine status cirrhotic noncirrhotic Participants cirrhosis must ultrasound image study within 6 month Screening visit Known coinfection human immunodeficiency virus ( HIV ) hepatitis B virus Prior discontinuation treatment interferon ribavirin due occurrence adverse event ( ) consider investigator possibly probably related treatment Treatment ribavirin within 90 day interferon within 1 month Screening visit Treatment investigational drug within 30 day prior Screening visit Treatment midazolam , pimozide , amiodarone , flecainide , propafenone , quinidine , ergot derivative within 2 week prior Day 1 visit Participation investigational trial within 30 day Screening visit Evidence decompensated liver disease Child Pugh score &gt; 6 ( Class B C ) Diabetic and/or hypertensive participant clinically significant ocular examination finding Preexisting psychiatric condition Clinical diagnosis substance abuse Active suspect malignancy Pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>